

D<sup>8</sup>  
Cont

phenotype in receptor-expressing cells, rather only an autonomous effect on ligand-expressing cells.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (pages i-v).

In the Claims

Please cancel Claims 1, 2, 8, 9, 22-41 and 44-71. Claims 3-7, 10-12, 42, 43, 72 and 75 have been amended and are presented below in amended form and new Claims 76-85 have been added. In accordance with 37 C.F.R. § 1.121(c)(1)(ii), amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages vi-vii).

- D<sup>9</sup>
3. (Amended) A method for altering angiogenesis in a mammal, comprising administering to the mammal, in a therapeutically effective quantity, a drug which alters the specific binding of an Ephrin family ligand with an Eph family receptor.
4. (Amended) The method of Claim 3 wherein angiogenesis is inhibited and the drug interferes with the specific binding of the Ephrin family ligand with the Eph family receptor.
- D<sup>10</sup>
5. (Twice Amended) The method of Claim 3 wherein angiogenesis is enhanced and the drug enhances specific binding of the Ephrin family ligand with the Eph family receptor.
6. (Amended) The method of Claim 3 wherein the drug is an antagonist of the Ephrin family ligand or an antagonist of the Eph family receptor.
- D<sup>11</sup>
7. (Amended) The method of Claim 3 wherein the Ephrin family ligand is EphrinB2 and the Eph family receptor is EphB4.

10. (Amended) A method for selectively delivering a drug to arteries in a mammal, comprising administering to the mammal a complex comprising:
- a) the drug; and
  - b) a component which binds an Ephrin family ligand, under conditions appropriate for the component of (b) to bind the Ephrin family ligand, whereby the drug is delivered to arteries.

- D12 11. (Amended) The method of Claim 10 wherein the drug is an anti-angiogenic drug and the component of (b) is an antibody specific for the Ephrin family ligand or a receptor of the Ephrin family ligand.

12. (Amended) The method of Claim 10 wherein the Ephrin family ligand is EphrinB2.

- D13 42. (Amended) A method for altering development of blood vessels in a mammal, comprising administering to the mammal a soluble polypeptide comprising the extracellular domain of an Ephrin family ligand or a soluble polypeptide comprising the extracellular domain of an Eph family receptor.

43. (Amended) The method of Claim 42 comprising administering to the mammal a soluble polypeptide comprising the extracellular domain of an Ephrin family ligand, wherein the Ephrin family ligand is EphrinB2.

- D14 72. (Amended) The method of Claim 10 wherein the drug is an angiogenic drug.

- D15 75. (Amended) The method of Claim 12 wherein the drug is an angiogenic drug.

- D16 76. (New) The method of Claim 3 wherein the drug is an agonist of the Ephrin family ligand or an agonist of the Eph family receptor.

77. (New) The method of Claim 76 wherein the agonist of the Ephrin family ligand is selected from the group consisting of:
- a soluble agonist comprising an extracellular domain of an Ephrin family ligand fused to an Fc domain of a human IgG antibody; and
  - a soluble agonist comprising an extracellular domain of an Eph family receptor fused to an Fc domain of a human IgG antibody.
78. (New) The method of Claim 10 wherein the drug is an anti-angiogenic drug.
79. (New) The method of Claim 10 wherein the drug is an angiogenic drug and the component of (b) is an antibody specific for the Ephrin family ligand or a receptor of the Ephrin family ligand.
80. (New) The method of Claim 42 comprising administering to the mammal a soluble polypeptide comprising the extracellular domain of an Eph family receptor, wherein the Eph family receptor is EphB4.
81. (New) The method of Claim 3 wherein the drug is a soluble agonist comprising an extracellular domain of an Ephrin family ligand fused to an Fc domain of a human IgG antibody or a soluble agonist comprising an extracellular domain of an Eph family receptor fused to an Fc domain of a human IgG antibody.
82. (New) The method of Claim 10 wherein the drug is an anti-plaque agent.
83. (New) The method of Claim 12 wherein the drug is an anti-plaque agent.

D16  
Cont.